Shares in biotechnology group Moderna (MRNA) were lower in pre-market trading after it posted a 35% fall in first quarter revenues to $108 million. A drop in Covid vaccination rates was partly to blame.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
It also reported a $971 million first-quarter loss, an improvement from the $1.18 billion loss in the same period last year.